BASEL, Switzerland, May  13, 2026  (GLOBE NEWSWIRE) -- Anaveon, a late-stage biotechnology company pioneering precision biologics to reprogram the immune system for the treatment of autoimmune and inflammatory diseases,

CLCD

Anaveon Appoints Thomas P. Mathers as Chair of the Board of Directors

New Chair Appointment at Anaveon Could Boost Future Growth

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>BASEL, Switzerland, May  13, 2026  (GLOBE NEWSWIRE) -- Anaveon, a late-stage biotechnology company pioneering precision biologics to reprogram the immune system for the treatment of autoimmune and inflammatory diseases,</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Anaveon announced the appointment of Thomas P. Mathers as Chair, enhancing strategic leadership at a crucial time. His extensive experience in biotechnology and capital raising may drive significant growth, particularly in advancing clinical programs and new drug candidates.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Anaveon appoints Thomas P. Mathers as Chair of Board of Directors.</li><li>Mathers has extensive experience in the biotechnology sector and capital raising.</li><li>His leadership will enhance Anaveon&#039;s clinical development and strategic execution.</li><li>Mathers previously led CoLucid Pharmaceuticals, boosting its valuation before acquisition.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Anaveon AG (N/A)</strong>: Appointment of a seasoned leader suggests strategic growth ahead.</li><li><strong>CoLucid Pharmaceuticals (CLCD)</strong>: Mathers&#039; successful tenure at CLCD may hint at future successes.</li><li><strong>Eli Lilly (LLY)</strong>: Lilly&#039;s acquisition of CLCD indicates high value in pharma M&amp;A.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This announcement fits &#039;Corporate Developments&#039;, emphasizing leadership changes that can steer strategic objectives and impact clinical innovations for new and existing therapies.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Mathers&#039; appointment might enhance investor confidence in Anaveon&#039;s pipeline strengths.</li><li>Improved financing strategies under Mathers could unlock additional growth opportunities.</li><li>The success of Anaveon’s clinical programs may positively influence market sentiment for CLCD.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Thomas P. Mathers brings over 32 years of biotech experience.</li><li>Mathers led CoLucid Pharmaceuticals to a $1 billion acquisition.</li><li>He has served in senior roles at several biotechnology firms.</li><li>Anaveon focuses on precision biologics for autoimmune disease treatment.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Consider acquiring CLCD shares as Mathers&#039; leadership may lead to positive growth catalysts.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>BASEL, Switzerland, May  13, 2026  (GLOBE NEWSWIRE) -- Anaveon, a late-stage biotechnology company pioneering precision biologics to reprogram the immune system for the treatment of autoimmune and inflammatory diseases, today announced the appointment of <strong>Thomas P. Mathers</strong> as Chair of its Board of Directors. His appointment will be confirmed in the upcoming Annual General Meeting in June. Dieter Weinand, who served as Chair since 2024, has stepped down from the Board.</p>  <p><strong>Mr. Mathers</strong> brings over 32 years of distinguished executive leadership in the life sciences sector, with a proven track record in company building, capital raising, public market transitions, and strategic value creation. As a Partner at Pappas Capital and Executive Chairman of Aer Therapeutics, he is widely recognized for his expertise in advancing innovative therapies from discovery through commercialization.</p>  <p>"We are thrilled to welcome Tom as Chair of Anaveon's Board at this pivotal moment," said <strong>Thaminda Ramanayake, Chief Executive Officer of Anaveon</strong>. "His exceptional experience in scaling biotechnology companies, securing substantial financing, and navigating complex regulatory and commercial landscapes will be invaluable as we advance our lead immunology programs into clinical development and expand our pipeline of novel drug candidates. We are deeply grateful to Dieter Weinand for his dedicated service and strategic guidance during a critical foundational period and wish him continued success."</p>  <p>"I am honored to join Anaveon as Chair of the Board," said Thomas P. Mathers. "The company's innovative approach to selectively modulating immune pathways has tremendous potential to deliver transformative therapies for patients with significant unmet needs in autoimmune diseases. I look forward to partnering with Thaminda, the executive team, and the Board to accelerate growth, strengthen strategic execution, and realize Anaveon's vision of reshaping immune-mediated disease treatment."</p>  <p><strong>Leadership in Action: Thomas P. Mathers' Track Record</strong></p>  <p>Mr. Mathers currently serves as Executive Chairman (and Interim CEO) of Aer Therapeutics, developing novel therapies for serious airway diseases, and as Vice Chairman of Certa Therapeutics, focused on fibrosis treatments. He is also Treasurer and a member of the Executive Committee of the Biotechnology Innovation Organization (BIO), where he actively shapes advocacy, regulatory policy, capital formation, bioethics, and intellectual property initiatives. He additionally serves on the U.S. Department of Veterans Affairs Research Advisory Committee on Gulf War Veterans' Illnesses.</p>  <p>In 2019, he founded Allievex Corp., a clinical-stage company developing therapies for neuronopathic lysosomal storage diseases such as Sanfilippo Syndrome. He led the company as President, CEO, and Director until its acquisition by Spruce Biosciences in 2024. Previously, as President and CEO of CoLucid Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/CLCD">CLCD</a>), he advanced lasmiditan for acute migraine treatment through key development milestones, culminating in its acquisition by Eli Lilly in 2017 for nearly $1 billion.</p>  <p>Earlier in his career, Mr. Mathers held senior leadership roles at Peptimmune, Cell Based Delivery, Cardion AG, and Genzyme Corporation. He holds a B.S. in Engineering from the United States Military Academy at West Point (1988), where he played varsity football. He served as a Captain and AH-64 Apache helicopter pilot in the U.S. Army during the Gulf War, earning multiple military honors.</p>  <p><strong>ENDS</strong></p>  <p><strong>Media contact:</strong><br></br>Benz Advisory<br></br>Beatrix Benz<br></br>Email: <a href="https://www.globenewswire.com/Tracker?data=gKgNeoabC1dDd-m_GV9gSYKA1KEzKd3OJPwu1NQ0Scl-yJROZpjvKiaaTJ6NHgeMjOllKgDAgMVryWUDJn7WAVQson2IMDyc_rjVBc3F9bQEk8nrvAWg3xt2nQi3Acve" rel="nofollow" target="_blank">beatrix.benz@anaveon.com</a><br></br>Tel: +41 79 256 77 73</p>  <p><strong>About Anaveon:</strong><br></br>Anaveon AG is a late-stage preclinical biotechnology company headquartered in Basel, Switzerland focused on developing next-generation precision biologics that target central regulatory nodes of the immune system. The company's engineered antibodies and cytokine-based therapies aim to selectively eliminate or reprogram pathogenic immune cells, restoring durable immune balance in autoimmune and inflammatory diseases.</p>  <p>For more information, visit <a href="https://www.globenewswire.com/Tracker?data=oL0DJbHSjM-IRi-kblDe2YwQRhldDcj5Jww7gUQ73wb18pyuzyp2wK16yJwoZpvfOUi0SU-GHOHUks2KkdYNdgQQVk50Lgwv_jf1PdX8S2w=" rel="nofollow" target="_blank"><strong>&gt;</strong> <strong>anaveon.com</strong></a></p>  <p>A photo accompanying this announcement is available at <a href="https://www.globenewswire.com/Tracker?data=4e2lBPbbVupCDjGIMAOeu7wYfkPPxnhF6UEZQ74qwRKDYWbkuqiYLOMckTXW7ZI78OfDgzZ6eYwlykm1E1b0yGoe48pJuSQUv612cTUnVy26Rhb2lmorjcHV1tGSGe3ms3b553x4t6d9MlwwkkN7KRwhd2PwC4qHqbo5pCiTSDmTOnLE4D9S4ll3rRAeCzhHQpYwVo9f5Vn7BP6Do6YEscxpq_GusLe_FCbiGJSwqMyYfJvHL5RyRouTXnzNnhCH-wKJ_Eg05BVVhB4G3fw7GA==" rel="nofollow" target="_blank">https://www.globenewswire.com/NewsRoom/AttachmentNg/9898afec-1c88-4bf2-9791-582f5321195b</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTcxODQ1NCM3NTk4MzI2IzIyMzI4Njg="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/Y2UyYWFhNDktYWE4Ny00YjNhLWE2ZDktNzhmOGJmYWNiNzExLTEyNDQ0MjEtMjAyNi0wNS0xMy1lbg==/tiny/Anaveon.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/376f71da-1a19-4a9a-bb0a-5d12feb63780"><img src="https://ml.globenewswire.com/media/376f71da-1a19-4a9a-bb0a-5d12feb63780/small/logo-anaveon-jpg.jpg" border="0" width="150" height="38" alt="Primary Logo"></img></a></p>

Anaveon announced the appointment of Thomas P. Mathers as Chair, enhancing strategic leadership at a crucial time. His extensive experience in biotechnology and capital raising may drive significant growth, particularly in advancing clinical programs and new drug candidates.

Anaveon Appoints Thomas P. Mathers as Chair of the Board of Directors

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News